KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Pharmacy Owners Say They Are Unable to Participate in MDPNP September 6, 2025The Medicare Drug Price Negotiation Program is anticipated to cause multiple issues for pharmacy owners and their cashflow sustainability.
- Olezarsen Demonstrates Favorable Reductions in Triglycerides for Hypertriglyceridemia September 5, 2025Olezarsen significantly reduces triglycerides and acute pancreatitis events, offering new hope for patients with severe hypertriglyceridemia.
- FDA Approves Medtronic’s MiniMed System for Type 2 Diabetes September 5, 2025Medtronic’s diabetes management technology reached 2 milestones upon FDA approval, allowing integration of continuous glucose monitoring for patients with type 1 and type 2 diabetes.
- How Real Patient Experiences Have Helped Bolster Advocacy for PBM Reform September 4, 2025After experiencing tragedy in his personal life, Bil Schmidtknecht was led to join the community of independent pharmacists and industry advocates calling for PBM reform across both aisles.
- COVID-19 Pandemic Significantly Impacts Pneumococcal Mortality Trends September 4, 2025Exploring the influences of pneumococcal disease mortality and events of the COVID-19 pandemic, researchers investigate changes in US pneumococcus survival rates since 2020.
- About 1 in 4 Pharmacies Dispense Buprenorphine, But Disparities Persist September 4, 2025In pharmacies in predominantly Black and Latino neighborhoods, only 18% and 17% were likely to carry buprenorphine compared with white neighborhoods.
- Orforglipron Shows Significant Weight Loss in New Phase 3 Study September 4, 2025Orforglipron shows results in weight loss and diabetes management, offering a new oral treatment option for patients.
- Hypertension Mortality Rose Significantly from 1999 to 2019 September 3, 2025With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.
- Achieving PBM Reform Through Public Engagement, Advocacy September 3, 2025Regardless of which stakeholders are involved, a collective, team effort is necessary to achieve state- and federal-level PBM reform.
- Transitions of Care and Unmet Needs in Hyperkalemia Management September 3, 2025An expert discusses the critical risks of care transitions for hyperkalemia patients, emphasizing the pharmacist’s essential role in ensuring medication safety, effective communication, and continuity of care, while highlighting the potential of predictive tools and novel therapies to improve early detection and long-term management.
Pharmacy Times articles
- Insights: NCCN Adds Zongertinib as Preferred Therapy for HER2-Mutant NSCLC September 6, 2025Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).
- AMCP CEO Raises Concerns Over ACIP Changes, Stresses Pharmacists’ Expanding Public Health Role September 5, 2025Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP), warns that politicizing the Advisory Committee on Immunization Practices (ACIP) could undermine vaccine trust.
- Efficacy, Safety, and Immunogenicity Maintained When Patients With nAMD Switch from Eylea to Biosimilar September 5, 2025Pavblu, a biosimilar to Eylea, also showed no clinically meaningful differences in efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).
- Smoking May Drive Pancreatic Cancer Progression, Study Finds September 5, 2025New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.
- FDA Grants Breakthrough Therapy Designation to Olomorasib With Pembrolizumab for NSCLC September 5, 2025The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.
- Blood Cancer Awareness Month: Advocacy, Education, and Empowering Communities September 5, 2025September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.
- Expert: Approvals of Updated COVID-19 Vaccines May Add Complexity to Fall Vaccination Season September 5, 2025Elizabeth Vaughan, MD, MPH, RD, highlights the key role pharmacists play in providing clear, trusted guidance for patients seeking COVID-19 vaccines this fall.
- Empowering Pharmacists to Use Their Training Can Help Patients, Expert Says September 5, 2025A chief pharmacy officer emphasizes the vital role of pharmacists in enhancing patient care, advocating for recognition, and integration within health care systems.
- Sifting Through Discordant Data From ESC 2025 September 5, 2025Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.
- Adagrasib Demonstrates Favorable PFS in Advanced KRASG12C-Mutated NSCLC September 5, 2025Compared with docetaxel, adagrasib shows significant progression-free survival (PFS) benefits in patients with non–small cell lung cancer (NSCLC).
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com